Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tropomodulin-4 (TMOD4) is a member of the tropomodulin protein family and the predominant isoform in mammalian skeletal muscle. It acts as an actin-capping protein, binding to the pointed (minus) end of actin filaments, where it blocks both elongation and depolymerization. This function is essential for regulating thin filament length, maintaining sarcomere structure, and enabling effective muscle contraction. TMOD4’s activity is tropomyosin-dependent; it helps ensure the integrity of myofibrils during muscle development. Disruption of TMOD4 impairs sarcomere assembly and muscle organization, and it may be genetically associated with certain myopathies and forms of amyotrophic lateral sclerosis. TMOD4 is not known to be a direct target of any current drugs, nor is it used as a clinical biomarker or therapeutic agent.
no drugs known to act via TMOD4, so no therapeutic mechanism; its biological role is actin filament capping and stabilization
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tropomodulin-4 (TMOD4).